Skip to main content

Biosimilar Substitution Laws

Loading...

About this dataset:

This map shows how state laws vary on pharmacists’ ability to autonomously substitute biologics with products called “biosimilars.” Biologics are vaccines and other therapeutic products isolated from human, animal or microorganism tissues and cells, used to treat cancer and other complex diseases. Biosimilars are biological products that are highly similar to a previously approved biologic, as the name implies.

State laws that regulate biosimilar substitution identify criteria that must be met for substitution to occur, require pharmacists to notify prescribers and patients of any substitution, define recordkeeping and labeling requirements, and address pharmacists’ liability for choosing to substitute biosimilars.

Dataset Created by
Center for Public Health Law Research

Dataset Maintained by
Center for Public Health Law Research

Dataset Valid From
03/01/2016

Dataset Updated Through
10/01/2017

Total Jurisdictions Covered
51

Contact
Jon Larsen (jonathan.larsen@temple.edu)

Cite this dataset

Temple University Center for Public Health Law Research (2017, October 1). Biosimilar Substitution Laws. LawAtlas.org. Lawatlas.org/datasets/biosimilars-laws

COPY APA
Temple University Center for Public Health Law Research (October 1, 2017). “Biosimilar Substitution Laws”. LawAtlas.org. Lawatlas.org/datasets/biosimilars-laws
Copied to clipboard